Income from Continuous Operations: A company's total income or loss before discontinued operations, extraordinary items, preferred stock dividends and accounting change.
Akero Therapeutics, Inc. (AKRO) had Income from Continuous Operations of $-81.57M for the most recently reported fiscal quarter, ending 2025-09-30.
| Income Statement Financials | |
-- |
|
$-81.57M |
|
-- |
|
-- |
|
$90.24M |
|
$-90.24M |
|
$8.67M |
|
$-81.57M |
|
$-81.57M |
|
$-81.57M |
|
|
Income from Continuous Operations |
$-81.57M |
$-81.57M |
|
$-81.57M |
|
$-90.24M |
|
$-92.49M |
|
82.01M |
|
82.01M |
|
$-0.99 |
|
$-0.99 |
|
| Balance Sheet Financials | |
$754.53M |
|
-- |
|
$251.04M |
|
$1.01B |
|
$47.65M |
|
-- |
|
$0.29M |
|
$47.94M |
|
$957.64M |
|
$957.64M |
|
$957.64M |
|
80.15M |
|
| Cash Flow Statement Financials | |
$-183.08M |
|
$-346.06M |
|
$364.94M |
|
$340.24M |
|
$176.03M |
|
$-164.21M |
|
$27.10M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
15.83 |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
$-183.08M |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-8.52% |
|
-8.52% |
|
-8.11% |
|
-8.52% |
|
$11.95 |
|
$-2.23 |
|
$-2.23 |
|